Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study

Kagabu, Masahiro; Shoji, Tadahiro; Murakami, Kazuyuki; Omi, Hideo; Honda, Tatsuya; Miura, Fumiharu; Yokoyama, Yoshihiko; Tokunaga, Hideki; Takano, Tadao; Ohta, Tsuyoshi; Shimizu, Dai; Sato, Naoki; Soeda, Shu; Watanabe, Takafumi; Yamada, Hidekazu; Mizunuma, Hideki; Yaegashi, Nobuo; Nagase, Satoru; Tase, Toru; Sugiyama, Toru

doi:10.1007/s10147-016-0946-4

Cited by 7 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer Unit study (14) demonstrated that nedaplatin-based postoperative CCRT was an effective and well-tolerated regimen for both early-stage and advanced-stage cervical cancer patients, with similar PFS, OS, and toxicities. It was efficacious and safe, with no renal toxicity for FIGO stage IB2-IVA cervical cancer (15).…”

Section: Discussionmentioning

confidence: 99%

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial

Wang

Lai

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundIn this trial, we aimed to assess the efficacy and safety of radiotherapy with nedaplatin or cisplatin in patients with locally advanced cervical cancer.MethodsWe conducted an open-label, non-inferiority, phase III, randomized, controlled trial. Eligible patients with stage IIB-IVA cervical carcinoma were randomly assigned to receive either nedaplatin or cisplatin for two cycles concurrently with radiotherapy. We reported the therapy-associated harms and survival. The study was registered with chictr.org.cn, number ChiCTR1800020527.ResultsWe randomly assigned 68 patients to nedaplatin-based or cisplatin-based concurrent chemoradiotherapy. Study treatment was stopped early after a data analysis found a higher number of patients suffered severe hematologic harms in the nedaplatin group than in the cisplatin group. Patients in the nedaplatin group had a significantly higher frequency of grade 3-4 neutropenia (19·4% vs. 13%; P < 0·001), severe thrombocytopenia (16·1% vs. 4·3%), and grade 1-2 anemia (51·6% vs. 43·5%) than patients in the cisplatin group. The 1-year PFS and OS in the nedaplatin and cisplatin groups were similar.ConclusionOur findings showed that nedaplatin-based concurrent chemoradiotherapy expressed remarkably higher severe hematologic harms which were mortal. Though the results were negative, the experiences and lessons we learned from it were important.

show abstract

Section: Discussionmentioning

confidence: 99%

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial

Wang

Lai

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Our results are inconsistent with a study reported by Chinese scholars for locally advanced cervical cancer, 9 but in accordance with multiple studies in Japan, which supported the use of nedaplatin as an alternative for CCRT in cervical cancer. 14 , 15 , 18 , 19 , 20 Our trial showed that patients undergoing nedaplatin-based CCRT had similar overall survival and progression-free survival with cisplatin-based CCRT.…”

Section: Discussionmentioning

confidence: 88%

“… 13 These results, however, contradict multiple previous researches indicating that nedaplatin-based CCRT is safe and effective for cervical cancer patients. 14 , 15 , 18 , 19 , 20…”

Section: Discussionmentioning

confidence: 99%

“…Our findings are also consistent with multiple studies reported by Japanese scholars. 14 , 18 , 19 , 20 Compared with cisplatin-treated patients, patients treated with nedaplatin-based concurrent chemotherapy had similar overall survival and improved gastrointestinal and renal toxicity. The 3-year overall survival rate in the nedaplatin-based CCRT group in our trial (98.75%) was higher than that in the trial (92%) reported by Kagabu et al.…”

Section: Discussionmentioning

confidence: 99%

“… 13 Japanese researchers Kagabu et al. 14 found no significant difference in toxicity between cisplatin- or nedaplatin-based postoperative CCRT for cervical cancer. A meta-analysis concluded that nedaplatin could be used as an alternative for patients who cannot tolerate the side-effects of cisplatin in cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer

Yang

Ren

et al. 2022

ESMO Open

View full text Add to dashboard Cite

Hypomagnesemia because of nedaplatin for cervical cancer: A case report

Komoda,

Hori,

Sato

et al. 2023

J of Gen and Family Med

View full text Add to dashboard Cite

A 76-year-old woman with cervical cancer was treated with nedaplatin, a platinumbased drug. After the initiation of the treatment, she became aware of numbness, dizziness, and loss of appetite. Exploration of the causes revealed no clues, but blood tests revealed hypocalcemia and hypomagnesemia. She was treated with intravenous calcium and magnesium, which resolved calcium, magnesium levels, and her symptoms. She was diagnosed with hypomagnesemia because of nedaplatin. Regular follow-up is necessary for patients during or after nedaplatin. Awareness of electrolyte disturbances may elucidate the accurate diagnosis even in patients with obscure symptoms, particular in undergoing or following anticancer therapies.

show abstract

Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study

Abstract: Nedaplatin-based postoperative CCRT is an effective and well-tolerated regimen for both early-stage and advanced-stage cervical cancer patients.

Cited by 7 publications

References 21 publications

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial

Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Patients With Stage IIB-IVA Cervical Cancer: A Randomized Phase III Trial

A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer

Hypomagnesemia because of nedaplatin for cervical cancer: A case report

Contact Info

Product

Resources

About